Francisco J. Esteva
Francisco J. Esteva
Research Professor, NYU School of Medicine
Geverifieerd e-mailadres voor nyulangone.org
Titel
Geciteerd door
Geciteerd door
Jaar
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata, KH Lan, X Zhou, M Tan, FJ Esteva, AA Sahin, KS Klos, P Li, ...
Cancer cell 6 (2), 117-127, 2004
19932004
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
R Nahta, D Yu, MC Hung, GN Hortobagyi, FJ Esteva
Nature clinical practice Oncology 3 (5), 269-280, 2006
10732006
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
R Nahta, LXH Yuan, B Zhang, R Kobayashi, FJ Esteva
Cancer research 65 (23), 11118-11128, 2005
8622005
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer
J Baselga, V Semiglazov, P Van Dam, A Manikhas, M Bellet, ...
Journal of Clinical Oncology 27 (16), 2630-2637, 2009
7372009
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer
FJ Esteva, V Valero, D Booser, LT Guerra, JL Murray, L Pusztai, ...
Journal of Clinical Oncology 20 (7), 1800-1808, 2002
7032002
Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
AD Seidman, MN Fornier, FJ Esteva, L Tan, S Kaptain, A Bach, ...
Journal of Clinical Oncology 19 (10), 2587-2595, 2001
6902001
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
CM Sturgeon, MJ Duffy, UH Stenman, H Lilja, N Brunner, DW Chan, ...
Clinical chemistry 54 (12), e11-e79, 2008
685*2008
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta, MC Hung, FJ Esteva
Cancer research 64 (7), 2343-2346, 2004
6692004
Herceptin: mechanisms of action and resistance
R Nahta, FJ Esteva
Cancer letters 232 (2), 123-138, 2006
5422006
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor …
AU Buzdar, V Valero, NK Ibrahim, D Francis, KR Broglio, RL Theriault, ...
Clinical Cancer Research 13 (1), 228-233, 2007
5382007
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
S Zhang, WC Huang, P Li, H Guo, SB Poh, SW Brady, Y Xiong, LM Tseng, ...
Nature medicine 17 (4), 461-469, 2011
5172011
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
AD Seidman, CA Hudis, J Albanell, J Albanel, W Tong, I Tepler, V Currie, ...
Journal of Clinical Oncology 16 (10), 3353-3361, 1998
4891998
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
LA Carey, HS Rugo, PK Marcom, EL Mayer, FJ Esteva, CX Ma, MC Liu, ...
Journal of clinical oncology 30 (21), 2615, 2012
4812012
HER2 therapy: molecular mechanisms of trastuzumab resistance
R Nahta, FJ Esteva
Breast Cancer Research 8 (6), 1-8, 2006
4802006
Planning cancer control in Latin America and the Caribbean
PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ...
The Lancet Oncology 14 (5), 391-436, 2013
4482013
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience
V Guarneri, DJ Lenihan, V Valero, JB Durand, K Broglio, KR Hess, ...
Journal of Clinical Oncology 24 (25), 4107-4115, 2006
3972006
Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3
DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ...
J Clin Oncol 36 (24), 2465-2472, 2018
3922018
Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: American Society of Clinical Oncology clinical practice guideline
SH Giordano, S Temin, JJ Kirshner, S Chandarlapaty, JR Crews, ...
Journal of clinical oncology 32 (19), 2078, 2014
3802014
Residual risk of breast cancer recurrence 5 years after adjuvant therapy
AM Brewster, GN Hortobagyi, KR Broglio, SW Kau, CA Santa-Maria, ...
Journal of the National Cancer Institute 100 (16), 1179-1183, 2008
3792008
P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells
R Nahta, T Takahashi, NT Ueno, MC Hung, FJ Esteva
Cancer research 64 (11), 3981-3986, 2004
3542004
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20